Overview

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

Status:
Unknown status

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this prospective study is to determine the safety and feasibility of pharmacokinetically (PK) guided dosing of sunitinib in 30 patients. At day 15 ± 1day, day 29 ± 1day and after 8 weeks ± 1day of sunitinib treatment sunitinib and SU12662 trough levels will be measured. Depending on the sunitinib and SU12662 trough levels (and toxicity) dose adjustments will be made.

Phase:

Phase 1

Details

Lead Sponsor:

The Netherlands Cancer Institute

Collaborator:

Pfizer

Treatments:

Sunitinib